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Abstract PYRIN-containing Apaf-1-like proteins (PYPAFs)
are a recently identi¢ed family of proteins thought to function
in apoptotic and in£ammatory signaling pathways. PYPAF1
and PYPAF7 proteins have been found to assemble with the
PYRIN^CARD protein ASC and coordinate the activation of
NF-UB and pro-caspase-1. To determine if other PYPAF family
members function in pro-in£ammatory signaling pathways, we
screened ¢ve other PYPAF proteins (PYPAF2, PYPAF3, PY-
PAF4, PYPAF5 and PYPAF6) for their ability to activate NF-
UB and pro-caspase-1. Co-expression of PYPAF5 with ASC
results in a synergistic activation of NF-UB and the recruitment
of PYPAF5 to punctate structures in the cytoplasm. The ex-
pression of PYPAF5 is highly restricted to granulocytes and
T-cells, indicating a role for this protein in in£ammatory signal-
ing. In contrast, PYPAF2, PYPAF3, PYPAF4 and PYPAF6
failed to colocalize with ASC and activate NF-UB. PYPAF5
also synergistically activated caspase-1-dependent cytokine pro-
cessing when co-expressed with ASC. These ¢ndings suggest
that PYPAF5 functions in immune cells to coordinate the trans-
duction of pro-in£ammatory signals to the activation of NF-UB
and pro-caspase-1.
4 2002 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
Apaf-1 plays a central role in apoptosis by transducing pro-
apoptotic signals to the activation of pro-caspase-9 [1,2]. Dur-
ing apoptosis, cytochrome c is released from mitochondria
into the cytoplasm, where it induces the oligomerization of
Apaf-1 in the presence of dATP. Oligomerization of Apaf-1
results in the formation of an apoptosome that recruits and
activates pro-caspase-9. Apaf-1 has a tripartite domain struc-
ture consisting of an N-terminal caspase-recruitment domain
(CARD) that mediates recruitment of pro-caspase-9 to the
apoptosome, a central nucleotide-binding site (NBS) domain,
and a C-terminal domain comprised of WD-40 repeats. The
NBS domain mediates Apaf-1 oligomerization in the presence
of dATP, whereas the WD-40 repeats function as binding sites
for cytochrome c. Thus, Apaf-1 functions as a sensor-like
molecule that signals apoptosis in response to the release of
cytochrome c from mitochondria.
A search for Apaf-1-like molecules has resulted in the iden-
ti¢cation of numerous proteins that belong to the NBS/leu-
cine-rich repeat (LRR) family of in£ammatory regulators.
CARD4 (Nod1), CARD15 (Nod2) and CARD12 (Ipaf/
Clan) each contain an N-terminal CARD domain(s) that me-
diates assembly with a downstream signaling partner and a
central NBS domain that likely coordinates nucleotide-depen-
dent oligomerization [3^8]. In addition, each protein contains
a C-terminal LRR domain that has been proposed to function
as a binding site for speci¢c upstream regulators. CARD4 and
CARD15 signal the activation of NF-UB following assembly
with RICK, a CARD-containing kinase that mediates in£am-
matory signaling for both the innate and adaptive immune
systems [9,10]. Intriguingly, CARD15 variants confer suscep-
tibility to Crohn’s disease and Blau syndrome, two chronic
in£ammatory disorders [11^13]. In addition to coordinating
the activation of NF-UB, Apaf-1-like proteins have also
been found to regulate the activation of pro-in£ammatory
caspases. CARD12 is thought to play a critical role in in£am-
matory signaling by binding to and activating pro-caspase-1, a
CARD-containing caspase that processes pro-interleukin-1L
(IL-1L) and pro-interleukin-18 into active cytokines. The in-
£ammatory signals that regulate the assembly and activation
of these protein complexes are not presently understood.
A second group of Apaf-1-like proteins that contain N-ter-
minal PYRIN domains instead of CARD domains has been
identi¢ed recently [14^17]. We have named these proteins PY-
PAFs for PYRIN-containing Apaf1-like proteins [18,19]. The
PYRIN domain is a novel protein^protein interaction domain
that shares homology with pyrin, a protein that is associated
with a rare in£ammatory disorder called familial Mediter-
ranean fever [20]. This domain is a new member of the
death domain^fold superfamily that functions to mediate ho-
motypic interactions between PYRIN-containing proteins
[14,15,18,19]. PYPAF1 (cryopyrin) variants cause several
autoin£ammatory diseases, including Muckle^Wells syn-
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drome, familial cold urticaria, and chronic infantile neurolog-
ical cutaneous and articular syndrome [21^23]. We recently
identi¢ed PYPAF1 and PYPAF7 as PYPAF family members
that assemble together with ASC and signal the activation of
NF-UB and pro-caspase-1 [18,19]. The recruitment and acti-
vation of pro-caspase-1 by these PYPAF proteins is mediated
by the C-terminal CARD domain of ASC [19,24]. To deter-
mine if other PYPAF proteins regulate in£ammatory signal-
ing pathways, we screened ¢ve other family members for their
ability to activate NF-UB and pro-caspase-1. We report here
that ASC recruits PYPAF5 to distinct cytoplasmic loci. In
addition, PYPAF5 shows restricted expression to immune
cells and synergistically activates NF-UB and caspase-1 when
co-expressed with ASC. These ¢ndings identify PYPAF5 as a
cell-type-speci¢c upstream regulator of pro-in£ammatory sig-
naling pathways.
2. Materials and methods
2.1. Expression plasmids
Plasmids expressing full-length PYPAF2 (accession number
AF464764), PYPAF3 (accession number AF464765), PYPAF4 (acces-
sion number AF479747), PYPAF5 (accession number AF479748) and
PYPAF6 (accession number AY095145) with a C-terminal FLAG
epitope were constructed using either pCI (Promega) or pCMV-4
(PYPAF4, Stratagene). The plasmid expressing a PYPAF5 truncation
mutant lacking the PYRIN domain (PYPAF5vPYRIN, residues 81^
892) with a C-terminal FLAG epitope was also constructed using pCI
(Promega). Plasmids expressing mouse pro-IL-1L, pro-caspase-1,
dominant negative IKKQ and inactive pro-caspase-1 (C285) were de-
scribed previously [6,18].
2.2. PYPAF5 expression analysis
Total RNA from cells in culture was extracted (Qiagen) and ex-
pression pro¢les were determined by real time quantitative PCR anal-
ysis (Taqman1). In brief, an oligonucleotide probe (5P-ACG-
GAGCGGGCGTTCCTCTCCT-3P) was designed to anneal to
PYPAF5 between two PCR primers (forward: 5P-CCGTGTCCGAG-
Fig. 1. Domain structure of PYPAF family members. Shown are
PYPAF1, PYPAF2, PYPAF3, PYPAF4, PYPAF5, PYPAF6, PY-
PAF7, MATER (PYPAF8) and CARD7. PYRIN domains (red
shading), NBS domains (blue shading) and LRR domains (black
shading) are indicated.
Fig. 2. PYPAF5 is recruited to ASC punctate structures. HA-tagged
ASC (blue staining) and FLAG-tagged PYPAF proteins (red stain-
ing) were expressed in 293T cells. A^E show localization of PYPAF
proteins when expressed alone. F^J and K^O show the immuno-
staining patterns observed when each protein was co-expressed with
ASC. Note the co-localization of PYPAF5 (I and N) to the ASC
punctate structures (arrows).
Fig. 3. The PYRIN domain of PYPAF5 is needed for recruitment
to ASC punctate structures. HA-tagged ASC (blue staining) and
FLAG-tagged PYPAF5 proteins (red staining) were expressed in
293T cells. A and E show PYPAF5 and PYPAF5vPYRIN, respec-
tively, when expressed alone. B^D and F^H show the immunostain-
ing patterns observed when each protein was co-expressed with
ASC. Note the co-localization of PYPAF5 (B^D) and the lack of
co-localization of PYPAF5vPYRIN (F^H) to the ASC punctate
structures (arrows).
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TACAAGAAGAAG-3P and reverse: 5P-CGCGATGAGCAGCTTG-
GT-3P). The probe was then £uorescently labeled with FAM (reporter
dye) on the 5P end and TAMRA (quencher dye) on the 3P end. Probe
and PCR primers designed for L2 microglobulin were described pre-
viously [18]. PCR reactions were performed on cDNAs from various
cell types using primers and probes for both PYPAF5 and L2 micro-
globulin genes. Fluorescent emissions generated during PCR reaction
was measured by Sequence Detector 7700 (Perkin Elmer Life Scien-
ces). The expression level of PYPAF5 was normalized to the expres-
sion of L2 microglobulin for each sample.
2.3. Immunostaining assays
293T cells were transfected in poly-D-lysine-coated glass chamber
slides (BioCoat, Becton-Dickinson Labware) with plasmids expressing
HA-tagged ASC and FLAG-tagged PYPAFs using SuperFect trans-
fection reagent (Qiagen). Cells were ¢xed 24 h after transfection in 4%
paraformaldehyde, permeabilized and blocked in a bu¡er containing
0.3% Triton X-100, and incubated with the following primary and
secondary antibodies: rabbit anti-HA polyclonal Y-11 (Santa Cruz
Biotechnology), mouse anti-FLAG monoclonal antibody M2 (Sigma),
Alexa-350 goat anti-rabbit IgG (Molecular Probes), and Alexa-598
goat anti-mouse IgG (Molecular Probes).
2.4. Reporter gene assays
The NF-UB assay was described previously [25]. 293T cells were
transfected with pNF-UB luciferase reporter (Stratagene), pRL-TK
Renilla reporter (Promega), and indicated expression plasmids. Cells
were harvested and ¢re£y and Renilla luciferase activities were deter-
mined using the Dual-Luciferase reporter assay system (Promega).
2.5. IL-1L secretion assays
COS-7L cells (Gibco) were co-transfected in 12-well (22-mm) plates
using LipofectAMINE 2000 transfection reagent (Invitrogen) with
plasmids encoding mouse pro-IL-1L and indicated expression plas-
mids (total DNA=1.04 Wg). Supernatants were collected 24 h after
transfection and subjected to ELISA for mouse IL-1L according to
the manufacturer’s protocol (RpD Systems). The caspase-1 inhibitor
z-WEHD-FMK was added to cells following transfection at a ¢nal
concentration of 100 WM (RpD Systems).
3. Results and discussion
3.1. PYPAF family members are putative regulators of NF-UB
and caspase-1
The PYPAF family of signaling proteins is comprised of at
least eight members (Fig. 1). In addition, six other genes that
encode novel PYPAFs are also found in the HTG database of
genomic sequences (J. Bertin, unpublished data). Each family
member contains an N-terminal PYRIN domain, a central
NBS domain, and a C-terminal domain comprised of multiple
LRRs. In addition to these domains, CARD7 also contains a
C-terminal CARD domain and is therefore a member of both
the CARD and PYRIN protein families [14] (Fig. 1). We
recently identi¢ed PYPAF1 and PYPAF7 as upstream activa-
tors of NF-UB signaling and pro-caspase-1 [18,19]. The PYR-
IN^CARD protein ASC plays a central role in PYPAF1 and
PYPAF7 signaling by recruiting pro-caspase-1 to the PYPAF/
ASC signaling complex. In this study, we screened ¢ve other
PYPAF family members (PYPAF2, PYPAF3, PYPAF4, PY-
PAF5 and PYPAF6) for their ability to activate downstream
in£ammatory signaling pathways.
Fig. 4. Sequence and expression of PYPAF5. A: Amino acid sequence of PYPAF5. N-terminal PYRIN domain (residues 22^96, red shading),
NBS domain (residues 194^513) with seven consensus motifs that are found in the NACHT subfamily of NTPases (blue shading), and C-termi-
nal domain (residues 729^892) comprised of at least four LRRs. B: PYPAF5 expression in various immune cells by real time quantitative
PCR. Level of PYPAF5 expression in various cell types was normalized to the expression of L2 microglobulin.
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3.2. Recruitment of PYPAF5 to ASC punctate structures
We ¢rst performed cellular co-localization studies to deter-
mine whether the PYPAF proteins interact with ASC. FLAG-
tagged PYPAF2, PYPAF3, PYPAF4, PYPAF5 or PYPAF6
were co-expressed with HA-tagged ASC in cells and detected
using a mixture of anti-HA and anti-FLAG antibodies. When
expressed alone, the PYPAFs showed a broad cytoplasmic
distribution that excluded the nucleus (Fig. 2A^E). As ob-
served previously, ASC localized to cytoplasmic punctate
structures when expressed alone ([26], and data not shown).
However, PYPAF5 was found to co-localize with ASC when
co-expressed (Fig. 2I and N). PYPAF2, PYPAF3, PYPAF4
and PYPAF6 failed to be recruited to the ASC punctate struc-
tures (Fig. 2, compare F and K, G and L, H and M, J and O).
We also examined the ability of a PYPAF5 mutant lacking
the N-terminal PYRIN domain (PYPAF5vPYRIN) to be re-
cruited to the ASC punctate structures. When expressed
alone, PYPAF5vPYRIN showed a broad cytoplasmic distri-
bution similar to that of PYPAF5 (Fig. 3A and E). However,
PYPAF5vPYRIN failed to associate with the ASC punctate
structures, demonstrating that the PYRIN domain of PY-
PAF5 is necessary for recruitment (Fig. 3, compare B^D to
F^H). We have been unable to detect an interaction between
PYPAF5 and ASC by performing co-immunoprecipitation
experiments when both proteins are overexpressed in cells.
Our inability to detect an interaction is likely due to the tran-
sient nature of the interaction and/or the relative insolubility
of PYPAF5/ASC complexes that form in the cell when these
proteins are co-expressed. Nonetheless, the co-localization of
PYPAF5 to the ASC punctate structures is required for the
Fig. 5. PYPAF5 augments ASC-induced NF-UB activity. A: PYPAF5 synergizes with ASC to induce NF-UB activation. Plasmids expressing
PYPAFs (1000 ng) and ASC (32 ng) were transfected into 293T cells, and relative luciferase activities were determined to measure the induction
of NF-UB activity. B: PYPAF5 activates NF-UB in a concentration-dependent manner. C: The N-terminal PYRIN domain of PYPAF5 is re-
quired for synergy. 293T cells were transfected with plasmids expressing PYPAF5, and PYPAF5vPYRIN (1000 ng) with or without ASC (32
ng). The amount of DNAs in each transfection was kept constant by addition of empty vectors. Relative luciferase activities were then deter-
mined as a measure of NF-UB activity (lower panel). Immunoblot analysis shows expression of PYPAF5 and ASC (upper panels). D: PYPAF5
and ASC activate NF-UB through the IKK complex. 293T cells were transfected with plasmids expressing 32 ng of ASC and 500 ng of PY-
PAF5 with either 500 ng of empty vector or dominant negative mutants of IKKQ (IKKQ-DN) or IKK2 (IKK2-DN). Relative luciferase activ-
ities were then measured. Immunoblot analysis shows expression of PYPAF5 and ASC (upper panels).
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synergistic activation of NF-UB and caspase-1-dependent cy-
tokine processing (see below).
3.3. PYPAF5 is expressed in immune cells
PYPAF5 has a tripartite structure consisting of an N-ter-
minal PYRIN domain (residues 22^96), a central NBS do-
main (residues 194^513) and a C-terminal domain (residues
729^892) comprised of at least four LRR motifs (Fig. 4A).
The NBS domain belongs to the NACHT subfamily of
NTPases and contains seven signature motifs, including the
P-loop (residues 194^219, Fig. 4A) [27]. The PYRIN domain
of PYPAF5 shares signi¢cant sequence similarity with the
PYRIN domains of other PYRIN-containing proteins (data
not shown). To determine if PYPAF5 is expressed in immune
cells, peripheral blood leukocytes were fractionated into dis-
tinct cell populations. Quantitative real time PCR analysis
showed PYPAF5 to be predominantly expressed in granulo-
cytes with some expression in T-cells (Fig. 4B). Northern blot
analysis using a multiple tissue expression array (CLON-
TECH) showed little or no expression in other tissues and
cell lines (data not shown), suggesting a restricted expression
of PYPAF5 to immune cells.
3.4. Activation of NF-UB by PYPAF5
We next examined whether PYPAF5 participates in NF-UB
signaling pathways using a luciferase reporter plasmid. Ex-
pression of each PYPAF alone in cells failed to activate
NF-UB at all protein levels examined (data not shown). In
contrast, NF-UB was activated when high levels of ASC
were expressed in cells (data not shown; [18,19]). However,
when ASC was expressed at low protein levels that did not
activate NF-UB, co-expression with PYPAF5 resulted in a
potent activation of NF-UB (Fig. 5A, lane 6). Co-expression
of ASC with PYPAF2, PYPAF3, PYPAF4 or PYPAF6 failed
to activate NF-UB (Fig. 5A, lanes 3^5, 7). PYPAF5 activated
ASC-dependent NF-UB signaling in a concentration-depen-
dent manner (Fig. 5B). The N-terminal PYRIN domain of
PYPAF5 was essential for NF-UB signaling, since deletion
of this domain (PYPAF5vPYRIN) eliminated the synergistic
induction of NF-UB activity (Fig. 5C, compare lanes 4 and 6).
Immunoblot analysis revealed that ASC protein levels were
not increased when co-expressed with PYPAF5, demonstrat-
ing that the activation of NF-UB was not due to increased
levels of ASC (Fig. 5C, upper panels). NF-UB signaling oc-
curred through the IKK complex because dominant-negative
versions of IKK-Q and IKK-2 blocked the ability of PYPAF5
to synergistically activate NF-UB (Fig. 5D, lanes 3 and 4).
Taken together, these data demonstrate that PYPAF5 is an
activator of NF-UB signaling when co-expressed with ASC.
3.5. Activation of pro-caspase-1 by PYPAF5
We also examined whether PYPAF2, PYPAF3, PYPAF4,
PYPAF5 and PYPAF6 play a role in caspase activation and
cytokine processing. Active caspase-1 cleaves pro-IL-1L result-
ing in the release of IL-1L from cells. To measure the activa-
tion of pro-caspase-1, plasmids expressing pro-caspase-1 and
mouse pro-IL-1L were transfected into COS-7L cells with
plasmids encoding ASC and speci¢c PYPAF family members.
In this assay, the amount of murine IL-1L released into the
culture medium 1 day after transfection correlates with the
amount of intracellular caspase-1 activity [28]. When ASC
was expressed at protein levels that resulted in low levels of
caspase activity, co-expression with PYPAF5 resulted in a
synergistic activation of pro-caspase-1 and a corresponding
increase in IL-1L production (Fig. 6A). Co-expression of
ASC with PYPAF2, PYPAF3, PYPAF4 or PYPAF6 failed
to activate pro-caspase-1. The N-terminal PYRIN domain of
PYPAF5 was essential for pro-caspase-1 activation, since de-
letion of this domain (PYPAF5vPYRIN) eliminated the syn-
ergistic production of IL-1L (Fig. 6B, lane 7). Immunoblot
Fig. 6. PYPAF5 and ASC activate pro-caspase-1. COS-7L cells
were co-transfected with plasmids encoding mouse pro-IL-1L in
combination with various amounts of indicated plasmids encoding
pro-caspase-1, ASC and PYPAFs. After 24 h, supernatants were
collected and subjected to ELISA for IL-1L. A: Activation of pro-
caspase-1 by PYPAF5. B: Activation of pro-caspase-1 by PYPAF5
is dependent on its N-terminal PYRIN domain. C: PYPAF5 and
ASC induction of IL-1L secretion is dependent on active caspase-1.
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analysis revealed that PYPAF5vPYRIN was expressed at lev-
els similar to that of PYPAF5, indicating that loss of function
was not due to reduced protein levels (data not shown). PY-
PAF5 and ASC were unable to synergistically induce cytokine
expression when co-expressed with a caspase-1 active site mu-
tant (C285A) (Fig. 6C, lane 4). Furthermore, addition of a
caspase-1 inhibitor (z-WEHD) blocked the ability of PYPAF5
and ASC to induce the secretion of IL-1L (Fig. 6C, lane 3).
Taken together, these data demonstrate that PYPAF5 and
ASC synergistically activate pro-caspase-1.
3.6. Conclusions
In conclusion, we have identi¢ed PYPAF5 as a novel acti-
vator of pro-in£ammatory signaling pathways. Our ¢nding
that PYPAF5 is recruited to ASC punctate structures through
its N-terminal PYRIN domain suggests that these two pro-
teins assemble together into a complex that mediates signal
transduction. The restricted expression of PYPAF5 to periph-
eral blood leukocytes indicates a role for this PYPAF family
member in in£ammatory signaling. Our data further suggest
that PYPAF5 and ASC participate in the activation of both
NF-UB and pro-caspase-1. PYPAF5 may function in a man-
ner analogous to APAF-1 and activate ASC and pro-caspase-
1 through an induced proximity mechanism [29]. Both pro-IL-
1L and pro-IL-18 are processed by caspase-1, suggesting that
PYPAF5 may play an important role in cytokine production
and immune regulation [30]. PYPAF1 and PYPAF7 were also
recently found to activate pro-caspase-1 when co-expressed
with ASC, suggesting an analogous role for these proteins
in the production of IL-1 and IL-18 [18,19]. In this study,
PYPAF2, PYPAF3, PYPAF4 and PYPAF6 failed to co-local-
ize with ASC and activate NF-UB and pro-caspase-1, suggest-
ing that these PYPAF family members may regulate other
signal transduction pathways. Alternatively, these PYPAFs
could be folded in such a manner that renders them unable
to associate with ASC. The ¢ndings presented here indicate
the PYPAF5 belongs to a subgroup of PYPAF family mem-
bers that function to regulate NF-UB and cytokine produc-
tion.
References
[1] Zou, H., Henzel, W.J., Liu, X., Lutschg, A. and Wang, X. (1997)
Cell 90, 405^413.
[2] Li, P., Nijhawan, D., Budihardjo, I., Srinivasula, S.M., Ahmad,
M., Alnemri, E.S. and Wang, X. (1997) Cell 91, 479^489.
[3] Bertin, J., Nir, W.J., Fischer, C.M., Tayber, O.V., Errada, P.R.,
Grant, J.R., Keilty, J.J., Gosselin, M.L., Robison, K.E., Wong,
G.H., Glucksmann, M.A. and DiStefano, P.S. (1999) J. Biol.
Chem. 274, 12955^12958.
[4] Inohara, N, Koseki, T., del Peso, L., Hu, Y., Yee, C., Chen, S.,
Carrio, R., Merino, J., Liu, D., Ni, J. and Nunez, G. (1999)
J. Biol. Chem. 274, 14560^14567.
[5] Ogura, Y., Inohara, N., Benito, A., Chen, F.F., Yamaoka, S. and
Nunez, G. (2001) J. Biol. Chem. 276, 4812^4818.
[6] Geddes, B.J., Wang, L., Huang, W.-J., Lavellee, M., Manji,
G.A., Brown, M., Jurman, M., Cao, J., Morgenstern, J., Mer-
riam, S., Glucksmann, M.A., DiStefano, P.S. and Bertin, J.
(2001) Biochem. Biophys. Res. Commun. 284, 77^82.
[7] Poyet, J.L., Srinivasula, S.M., Tnani, M., Razmara, M., Fer-
nandes-Alnemri, T. and Alnemri, E.S. (2001) J. Biol. Chem.
276, 28309^28313.
[8] Damiano, J.S., Stehlik, C., Pio, F., Godzik, A. and Reed, J.C.
(2001) Genomics 75, 77^83.
[9] Kobayashi, K., Inohara, N., Hernandez, L.D., Galan, J.E., Nu-
nez, G., Janeway, C.A., Medzhitov, R. and Flavell, R.A. (2002)
Nature 416, 194^199.
[10] Chin, A.I., Dempsey, P.W., Bruhn, K., Miller, J.F., Xu, Y. and
Cheng, G. (2002) Nature 416, 190^194.
[11] Hugot, J.P., Chamaillard, M., Zouali, H., Lesage, S., Cezard,
J.P., Belaiche, J., Almer, S., Tysk, C., O’Morain, C.A., Gassull,
M., Binder, V., Finkel, Y., Cortot, A., Modigliani, R., Laurent-
Puig, P., Gower-Rousseau, C., Macry, J., Colombel, J.F., Sah-
batou, M. and Thomas, G. (2001) Nature 411, 537^539.
[12] Ogura, Y., Bonen, D.K., Inohara, N., Nicolae, D.L., Chen, F.F.,
Ramos, R., Britton, H., Moran, T., Karaliuskas, R., Duerr,
R.H., Achkar, J.P., Brant, S.R., Bayless, T.M., Kirschner, B.S.,
Hanauer, S.B., Nunez, G. and Cho, J.H. (2001) Nature 411, 603^
606.
[13] Miceli-Richard, C., Lesage, S., Rybojad, M., Prieur, A.M., Ma-
nouvrier-Hanu, S., Hafner, R., Chamaillard, M., Zouali, H.,
Thomas, G. and Hugot, J.P. (2001) Nat. Genet. 29, 19^20.
[14] Bertin, J. and DiStefano, P.S. (2000) Cell Death Di¡er. 7, 1273^
1274.
[15] Martinon, F., Hofmann, K. and Tschopp, J. (2001) Curr. Biol.
11, 118^120.
[16] Staub, E., Dahl, E. and Rosenthal, A. (2000) Trends Biochem.
Sci. 26, 83^85.
[17] Fairbrother, W.J., Gordon, N.C., Humke, E.W., O’Rourke,
K.M., Starovasnik, M.A., Jian-Ping, Y. and Dixit, V.M. (2001)
Protein Sci. 10, 1911^1918.
[18] Manji, G., Wang, L., Geddes, B., Brown, M., Merriam, S., Al-
Garawi, A., Mak, S., Lora, J.M., Briskin, M., Jurman, M., Cao,
J., DiStefano, P.S. and Bertin, J. (2002) J. Biol. Chem. 277,
11570^11575.
[19] Wang, L., Manji, G.A., Grenier, J.M., Al-Garawi, A., Merriam,
S., Lora, J.M., Geddes, B.J., Briskin, M., DiStefano, P.S. and
Bertin, J. (2002) J. Biol. Chem. 277, 29874^29880.
[20] The International FMF Consortium (1997) Cell 90, 797^807.
[21] Ho¡man, H.M., Mueller, J.L., Broide, D.H., Wanderer, A.A.
and Kolodner, R.D. (2001) Nat. Genet. 29, 301^305.
[22] Feldmann, J., Prieur, A-M., Quartier, P., Berquin, P., Certain, S.,
Cortis, E., Teillac-Hamel, D., Fischer, A. and de Saint Basile, G.
(2002) Am. J. Hum. Genet. 71, 198^203.
[23] Dode, C., Le Du, N., Cuisset, L., Letourneur, F., Berthelot,
J.M., Vaudour, G., Meyrier, A., Watts, R.A., Scott, D.G., Nich-
olls, A., Granel, B., Frances, C., Garcier, F., Edery, P., Boulin-
guez, S., Domergues, J.P., Delpech, M. and Grateau, G. (2002)
Am. J. Hum. Genet. 70, 1498^1506.
[24] Srinivasula, S.M., Poyet, J.-L., Razmara, M., Datta, P., Zhang,
Z.-J. and Alnemri, E.S. (2002) J. Biol. Chem. 277, 21119^
21122.
[25] Wang, L., Guo, Y., Huang, W.J., Ke, X., Poyet, J.L., Manji,
G.A., Merriam, S., Glucksmann, M.A., DiStefano, P.S.,
Alnemri, E.S. and Bertin, J. (2001) J. Biol. Chem. 276, 21405^
21409.
[26] Masumoto, J., Taniguchi, S., Ayukawa, K., Sarvotham, H.,
Kishino, T., Niikawa, N., Hidaka, E., Katsuyama, T., Higuchi,
T. and Sagara, J. (1999) J. Biol. Chem. 274, 33835^33838.
[27] Koonin, E.V. and Aravind, L. (2000) Trends Biochem. Sci. 25,
223^224.
[28] Lee, S.H., Stehlik, C. and Reed, J.C. (2001) J. Biol. Chem. 276,
34495^34500.
[29] Salvesen, G.S. and Dixit, V.M. (1999) Proc. Natl. Acad. Sci.
USA 96, 10964^10967.
[30] Fantuzzi, G. and Dinarello, C.A. (1999) J. Clin. Immunol. 19, 1^
11.
FEBS 26602 9-10-02 Cyaan Magenta Geel Zwart
J.M. Grenier et al./FEBS Letters 530 (2002) 73^7878
